- Results from HERMIONE, the Phase 2 clinical study of MM-302 in patients with HER2-positive metastatic breast cancer designed to support a potential Accelerated Approval application to the FDA, in 2017
Catalyst
Slingshot members are tracking this event:
Merrimack (MACK) Terminates Phase 2 HERMIONE Trial Evaluating MM-302 in HER2-Positive Locally Advanced or Metastatic Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MACK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2016
Occurred Source:
http://investors.merrimack.com/releasedetail.cfm?ReleaseID=1005127
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Data, Mm-302, Hermione, Her2-positive Breast Cancer
